A group of medications called BRAF inhibitors used in the
treatment of a particular type of skin cancer may promote wound healing
, according to a study conducted by researchers from the University of California and published in Nature Communications
‘Increased skin proliferation due to a side effect of BRAF inhibitors is a potential treatment for chronic wounds.’
due to injury or other causes interfere with the barrier function of the skin. They are difficult to treat and often require skin grafting
. Application of a local medicine to promote the skin healing process would definitely make treatment simpler and
less expensive. Researchers evaluated the topical use of an anticancer drug belonging to the group BRAF inhibitors called vemurafenib to aid the healing of skin wounds.
BRAF is a human gene which is capable of making a protein called B-Raf.The cancer-fighting BRAF inhibitors are drugs used for the treatment of a particular type of melanoma
, a potentially lethal skin cancer that arises from the pigment cells of the skin. These drugs block a mutated gene in the cancer cells, thereby causing the tumor to shrink.
One of the main side effects of BRAF
inhibitors is an excessive growth of skin. This occurs due to the activation of
the mitogen-activated protein kinase (MAPK) pathway at the cellular level. This
skin-related side effect of these drugs is being explored as a therapeutic
potential - to help the skin to re-grow and aid in wound healing.
Researchers tested the wound healing benefits of vemurafenib
in cell cultures as well as in animal studies. They found that:
The enhanced proliferation of skin cells was inhibited by trametinib - mitogen activated protein kinase enzyme inhibitor (MEK inhibitor), which blocks the MAPK activation.
- Vemurafenib promotes skin growth
in cell cultures grown in the laboratory
- Vemurafenib aids wound healing
when applied locally to a wound in animal studies
- The benefits were observed in two
mice models; in one model, an incision was made to create a wound and in
another, circular wounds were made and were prevented from closing through
skin contracture by attaching splinting rings
- The drug mainly promotes
proliferation of the skin cells called keratinocytes, which play an
important role in wound healing
- Various cellular and genetic signs
associated with wound healing were noted in the skin samples obtained from
these animal models
- The benefit of wound healing was
produced without giving rise to skin cancer
This confirms that the mitogen-activated protein kinase (MAPK) pathway is indeed responsible for the skin growth and thickening caused by vemurafenib.
The use of topical BRAF inhibitors is a
promising prospect for the treatment of wounds. However, they are still in the
testing process and there is still a long time before these drugs can be made
available for use in humans for this purpose.
- Escuin-Ordinas H et al. Cutaneous Wound Healing
Through Paradoxical MAPK Activation by BRAF Inhibitors. Nature Communications 7, Article number: 12348 doi:10.1038/ncomms12348